Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2025-05-29 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying them under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of regulatory approval from the Central Drugs Standard Control Organization for an additional indication of a pharmaceutical product. The content is an update on a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is short (1685 characters) and is an announcement of an event rather than a detailed report. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-05-29 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying them about regulatory approval received from the Central Drugs Standard Control Organization for an additional indication of a pharmaceutical product. It is an intimation under SEBI Listing Obligations and Disclosure Requirements Regulation 30, which typically covers material events or information that a listed company must disclose. The document does not contain financial data, earnings, or detailed reports but is an announcement of a regulatory approval event relevant to the company. It is not a financial report, earnings release, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-05-29 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-05-21 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board of Directors meeting scheduled for May 30, 2025. The agenda includes considering and approving audited financial results for the quarter and year ended March 31, 2025, and recommending dividends. The document also mentions the closure of the trading window for insider trading compliance. The document is short (1570 characters) and serves as a notification of a future event rather than containing any financial results or detailed reports. It does not contain actual financial data or results, nor is it a report itself. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance-related notifications that do not fit other categories.
2025-05-21 English
Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve 1. The audited financial ....
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board of Directors meeting scheduled for May 30, 2025. The agenda includes considering and approving audited financial results for the quarter and year ended March 31, 2025, and recommending dividends. The document also mentions the closure of the trading window for insider trading compliance. The document is short (1570 characters) and serves as a notification of a future board meeting and potential financial results approval, not the financial results report itself. Therefore, it is an announcement related to corporate governance and board activities, but not a full management or financial report. It fits best under Board/Management Information (MANG) as it announces a board meeting and its agenda.
2025-05-21 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of permission from a regulatory authority (Central Drugs Standard Control Organisation) for marketing a pharmaceutical product for an additional indication. The content is an official intimation about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is short (1755 characters) and it serves as an announcement to the stock exchanges rather than a detailed report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance documents that do not fit other specific categories.
2025-05-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.